Adial Pharmaceuticals, Inc. (ADIL) vs Moleculin Biotech, Inc. (MBRX)

Adial Pharmaceuticals, Inc. and Moleculin Biotech, Inc. are both Biotechnology companies. Adial Pharmaceuticals, Inc. and Moleculin Biotech, Inc. are of similar size ($11.3M and $11.2M). Adial Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Moleculin Biotech, Inc. trades at 0.1×. Across the 9 metrics below, Adial Pharmaceuticals, Inc. leads on 5 and Moleculin Biotech, Inc. on 4.

Valuation

Metric ADIL MBRX Biotechnology median
P/E n/m 0.05 7.88
P/S n/m n/m 11.47
P/B n/m 0.29 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.16 0.11 0.74
EV/Sales n/m n/m 10.73
Earnings yield (379.24%) 1,870.40% (28.84%)
Free cash flow yield (56.08%) (746.71%) (23.03%)

Profitability

Metric ADIL MBRX Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 352.60% (1,471.05%) (57.72%)
Return on assets (322.10%) (152.41%) (49.22%)
Return on invested capital 0.00% (417.27%) 0.00%

Growth

Metric ADIL MBRX Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 82.46% 82.01% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADIL MBRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.63 0.94 4.73
Net debt to EBITDA 0.75 0.35 0.96

Dividend

Metric ADIL MBRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ADIL MBRX Biotechnology median
Market cap 11.33m 11.17m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack